RDY - Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand | Benzinga
While Novo Nordisk A/S (NYSE:NVO) faces challenges in meeting the global demand for its highly sought-after weight-loss treatment, Wegovy, Indian drugmakers see an opportunity to enhance global access and affordability.
Indian pharmaceutical players, including Sun Pharma, Cipla, Dr. Reddy’s Laboratories Ltd (NYSE:RDY), and Lupin, are aggressively pursuing the development of their versions of Wegovy.
Industry analysts anticipate a significant increase in volume once the patents expire, making these drugs more accessible to a broader population.
In India, where high obesity rates and the second-highest number of people with type 2 diabetes prevail, the potential for the success of these drugs is substantial.
“We expect volume expansion to increase multi-fold ...